Reta

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reta

What is Reta? (Overview)

Property Description
Active ingredient Valsartan
Form Oral preparation (Tablet)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General purpose Managing blood pressure levels
Origin Synthetic compound

What Type of Medicine is Reta? (Classification and Identity)

Reta is a prescription-only medicine whose active component is Valsartan, which is formally classified as an Angiotensin II Receptor Blockers (ARB), a specific type of antihypertensive agent. This class of medication is clinically recognized for its systemic approach to reducing elevated blood pressure levels.

Reta is formulated as a single-ingredient product, focusing entirely on the therapeutic action of its core substance, Valsartan. Valsartan is a synthetic compound that operates as a non-peptide Angiotensin Receptor Antagonist, securing its place within the established group of cardiovascular drugs known as Sartans. Pharmacological data describes the compound's established mechanism in regulating vascular tone. Its use is typical in adults requiring maintenance therapy to keep their circulatory system regulated.


Form, Composition, and General Purpose

Reta is typically supplied as an oral preparation, most commonly in the form of a film-coated tablet, which is the designated route of administration. The general purpose of this medication class is to help reduce and maintain healthy blood pressure levels.

The composition involves the Valsartan active ingredient integrated with essential pharmaceutical excipients that ensure the tablet provides a stable, uniform dose. The drug achieves its general therapeutic benefit by selectively influencing the body's natural blood pressure control mechanisms, leading to vessel relaxation and reduced fluid retention. This targeted action lowers the resistance against which the heart must pump blood, providing a fundamental, long-term benefit to the circulatory system.

What side effects are possible with Reta?

Possible Side Effects and Safety Information


The safety profile for Reta, whose active ingredient is Valsartan, is systematically documented by government regulatory authorities, detailing potential adverse reactions classified by frequency and system-organ class. This information is derived from official prescribing labels and clinical data.

The most frequently reported adverse reactions, classified as common in official documents, include dizziness, headache, fatigue, and hypotension (low blood pressure). A cough and hyperkalaemia (elevated potassium levels) are also listed in this frequency category. Reactions classified as uncommon include vertigo, diarrhea, abdominal pain, arthralgia (joint pain), and renal function impairment. Some effects, such as hypotension and dizziness, may be more likely at the initiation of treatment or following a dose increase, as noted in official prescribing information.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight serious adverse reactions, which include Angioedema—a rare but significant swelling of the face, lips, tongue, and throat. Acute renal failure and severe symptomatic hypotension are also documented safety concerns. The official safety constraints include the explicit warning that this medication should not be used in individuals with severe hepatic impairment (severe liver problems). Additionally, the label notes that the risk of worsening renal function may be increased with co-administration of certain medications, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and that the medicine must be discontinued immediately if pregnancy is detected due to the potential for fetal toxicity.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Reta (Valsartan) primarily results in an exaggeration of the therapeutic effect, leading to severe cardiovascular compromise. The key clinical manifestation documented in regulatory labeling is Marked Hypotension (excessive low blood pressure), which may be accompanied by dizziness.


Severe Manifestations and Emergency Action

Aspect Official Regulatory Statement
Life-Threatening Outcomes The profound hypotension can escalate to depressed level of consciousness, circulatory collapse, and shock.
Required Urgent Action Seek immediate medical attention for any symptomatic overdose. Stabilisation of the circulatory condition is of prime importance.
Supportive Management Treatment involves symptomatic and supportive measures, including placing the patient in a supine position and correcting blood volume, often via intravenous infusion of normal saline solution.
Antidote Status No specific antidote is known. The drug is considered unlikely to be removed by haemodialysis.

The regulatory documents emphasize the potential for severe or life-threatening outcomes, mandating that the occurrence of symptomatic overdose immediately requires professional medical assessment. Continued clinical monitoring, including assessment of renal function, is advised due to the risk of complications associated with sustained severe hypotension.

Therapeutic Uses of Reta

What Reta Treats: Main Uses and Benefits

Reta is relevant for symptomatic relief, and may help maintain a sense of stability when symptoms are active. Medications in this class are used to help relieve pain, tenderness, swelling, and stiffness caused by conditions involving inflammatory or irritative states. Reta is commonly used in contexts where additional symptomatic support may be appropriate across key therapeutic domains.

It is relevant for managing conditions characterized by episodic or fluctuating manifestations, such as musculoskeletal strains and conditions presenting with systemic or localized discomfort. The medication is applied in addressing symptom clusters that may become intense or disruptive, and provides support that helps ease the overall symptom burden during periods of heightened symptoms.

Reta is considered relevant for managing symptoms related to physical discomfort, such as joint stiffness and localized swelling, which may interfere with daily functioning. By assisting in easing these challenging physical manifestations, the medication may help patients cope more steadily with symptom fluctuations, and assists with maintaining functional stability.


Quick Fact: Relief for Joint Stiffness


Regulatory References

  1. NIH MedlinePlus overview of similar medications

Eligibility and Restrictions for Use

Reta (Valsartan) eligibility is defined by strict regulatory criteria based on age, reproductive status, and specific underlying conditions. The official labeled criteria classify who can use the medicine and who is absolutely prohibited.

Contraindicated Populations

The medicine is contraindicated and must not be used in several specific populations. This includes women in the second and third trimesters of pregnancy due to the officially documented risk of fetal injury. It is also prohibited for patients with known hypersensitivity to Valsartan, those with severe hepatic impairment, including biliary cirrhosis and cholestasis, and diabetic patients who are concurrently taking the medicine Aliskiren.

Restricted and Conditional Use

Use is not recommended for breastfeeding mothers, children under 6 years of age, or pediatric patients under 18 for heart failure due to a lack of established safety data. Patients with severe renal impairment (low Glomerular Filtration Rate) are also generally not recommended to use the medicine. Special caution is required for patients with a history of angioedema or certain cardiovascular conditions like aortic or mitral valve stenosis. For adults with mild to moderate hepatic or renal impairment, use is generally permitted, though caution is still advised.

What should I know about interactions with other medicines?

Reta (Valsartan) has officially documented interaction patterns that primarily involve pharmacodynamic effects on the Renin-Angiotensin System (RAS) and potassium homeostasis.

Formal Restrictions and Contraindications

The co-administration of Valsartan with Aliskiren is formally classified as a contraindication for patients with diabetes mellitus or moderate-to-severe renal impairment. This is an example of a population-specific interaction restriction. Similarly, the dual blockade of the RAS through co-administration with an ACE Inhibitor is officially documented as being associated with an increased risk of hypotension, hyperkalemia, and renal impairment.

Pharmacodynamic Interactions

Due to the risk of hyperkalemia (high serum potassium), the concurrent use of Valsartan is not recommended with agents that increase serum potassium. These include potassium-sparing diuretics and potassium supplements. An additional pharmacodynamic concern exists with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); co-administration may lead to an increased risk of renal impairment and a documented reduction in the medicine's blood pressure-lowering effect.

Exposure-Altering Interaction

Valsartan has a specific documented interaction that alters the plasma exposure of another drug. Co-administration with Lithium is associated with an official rise in serum lithium concentrations, which increases the risk of toxicity and necessitates monitoring. The overall interaction profile is characterized by restrictions based on the patient's underlying condition and the risk of combined physiologic effects.

Mechanism of Action

The Triple Receptor Agonism Mechanism

Reta's core molecular mechanism is its action as a triple agonist on three key receptors: the Glucagon-Like Peptide-1 receptor (GLP-1R), the Glucose-Dependent Insulinotropic Polypeptide receptor (GIPR), and the Glucagon receptor (GCGR). This concurrent activation initiates G-protein-mediated signaling cascades that influence the regulation of glucose and energy balance across biological systems.

Central and Peripheral Metabolic Modulation

This mechanism exerts central action on satiety and peripheral action on glucose and lipid metabolism. By influencing neural pathways in the brain, the drug contributes to modulation of central appetite signaling, affecting feeding behavior. Peripherally, the action promotes the breakdown of fat (lipolysis) and influences the rate of energy utilization in metabolic tissues.

Mechanistic Cascade for Metabolic Control

The activation triggers specific cascades resulting in defined metabolic alterations. This includes glucose-dependent insulin secretion and the suppression of the counter-regulatory hormone glucagon in the pancreas, as well as enhancing hepatic lipid oxidation in the liver, which collectively influences the lowering of circulating glucose and the adjustment of body lipid stores.

Dosage and Administration Information

How to Use Reta (Valsartan)

Reta (Valsartan) is an oral preparation administered in accordance with clinical dosing regimens. The medication is taken consistently, and guidelines permit administration with or without food. Dosing is variable, specifically determined by the condition being managed.


Standard Administration Schedules

The frequency and dosage are fixed according to the specific indication, starting with a low dose and gradually increasing (titrating) over time to reach a long-term maintenance dose. The medication is available in strengths including 40 mg, 80 mg, 160 mg, and 320 mg film-coated tablets.

Condition Initial Dosing Regimen Maximum Recommended Dosing
Hypertension 80 mg or 160 mg once daily Up to 320 mg once daily
Heart Failure 40 mg twice daily (BID) Up to 160 mg twice daily
Post-MI Treatment 20 mg twice daily, started 12 hours post-MI Up to 160 mg twice daily

For chronic conditions like hypertension, the maximal blood pressure effect is generally achieved after four weeks of consistent daily therapy. Dose adjustments for heart failure are typically performed at intervals of at least two weeks.

Administration Details for Specific Populations

For patients with mild to moderate hepatic impairment without cholestasis, the dose is constrained and should not exceed 80 mg. No initial dose adjustment is required for older adults or those with mild to moderate renal impairment. For pediatric patients, a specific oral suspension may be compounded, which requires precise dosage adjustment as it results in greater systemic exposure compared to the tablet form.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Episodic and Chronic Migraine

Research explored the measurement of changes in migraine attack frequency and duration among participants. Studies across Phase 2 and Phase 3 trials have evaluated the drug’s performance in both episodic and chronic migraine populations.

  • Episodic Migraine: A pooled analysis of four randomized, placebo-controlled trials examined changes in mean monthly migraine days (MMDs) among participants with episodic migraine. These studies also documented the proportion of participants who reported a symptom change at the two-hour post-administration time point.
  • Chronic Migraine: A 12-week, double-blind, placebo-controlled trial examined the effect on MMDs in participants diagnosed with chronic migraine. A change in monthly migraine days was noted over a 12-month period in study participants. The effect on severe migraine episodes was investigated in relation to time to symptom reduction.

Tolerability and Adverse Event Profile

The tolerability and adverse event profile of the drug was monitored over long-term observation. The reported adverse events were generally categorized as mild or moderate in severity by study investigators.

  • Common Side Effects: The most frequently reported adverse events included injection site reactions, constipation, and muscle cramps.
  • Long-Term Tolerability: Open-label extension studies evaluated the tolerability of the drug over a period extending up to two years. Study participants were administered the drug exactly as prescribed. The drug’s adverse event profile was documented in comparison to older treatments during the trials.

Co-Administration

Studies evaluated the tolerability and effect of co-administration with standard prophylactic treatments, including topiramate and propranolol.

Frequently Asked Questions (FAQ)

Common questions about Reta (FAQ)

Q: How quickly does Reta typically start to have an effect?

A: According to official product information, the initial blood pressure-lowering activity from a single dose generally begins approximately two hours after Reta is taken. This marks the start of the drug's documented effect on the circulatory system.

Q: How long does it usually take to feel the full benefits of Reta?

A: For the management of high blood pressure, the maximal blood pressure-lowering effect is generally attained after four weeks of taking the medication consistently every day. Official data indicates that the therapeutic effect is optimized over this four-week period.

Q: Do I have to take Reta for a long time, or is it a short-term treatment?

A: Reta is indicated for managing chronic, long-term conditions, including high blood pressure and heart failure. Management of these conditions is generally considered long-term. Official guidance supports consistent use over time for therapeutic management.

Q: Is it normal to feel slightly nauseous or dizzy when first starting Reta?

A: Dizziness is a common adverse reaction reported in clinical trials, and low blood pressure (hypotension) is noted, especially when treatment is first started. Nausea is also listed as an adverse event in some patient populations. Official data indicates these effects were generally transient in clinical trials.

Q: Does Reta interact with common over-the-counter medicines like pain relievers?

A: Yes, regulatory documentation notes an interaction concern with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Taking Reta with common OTC pain relievers such as ibuprofen is documented to potentially increase the risk of kidney function impairment, a consideration detailed in official labeling.

Q: Can Reta affect my ability to drive or operate machinery?

A: Official information indicates that, like many medicines for blood pressure, Reta may occasionally cause side effects such as dizziness or fatigue. If side effects such as dizziness occur, they may temporarily affect the ability to concentrate and perform skilled tasks, such as driving or operating machinery.

Q: Are there any specific foods or beverages I should avoid while taking Reta?

A: Regulatory documents indicate that caution is advised regarding potassium-rich foods or salt substitutes containing potassium. Reta may increase potassium levels in the blood, and co-consumption of additional potassium sources is a documented concern in official regulatory warnings.

Q: Are there any long-term studies available for Reta's effects?

A: Yes, the tolerability and safety profile of the drug have been documented over long periods in clinical development. This includes open-label extension studies, which track patient outcomes and adverse events over an extended time, in some cases documented up to two years.

Q: What happens in the body if Reta is taken with high-fat meals?

A: Pharmacokinetic studies have shown that taking Reta with food generally reduces the amount of the drug absorbed by the body. Specifically, a high-fat meal is documented to decrease the body's exposure to Valsartan by up to 40% compared to taking it on an empty stomach.

Q: What kind of studies provided the primary evidence for Reta's approval?

A: The initial regulatory approval of Reta was based on evidence primarily gathered through randomized, placebo-controlled clinical trials, including Phase 2 and Phase 3 studies. These trials evaluated the drug's effectiveness in lowering blood pressure and managing its indicated conditions.

Q: Does taking Reta with food change how the medicine is absorbed?

A: Yes, official regulatory labeling documents that consuming Reta with food has been shown to reduce the overall extent to which the medicine is absorbed by the body. This characteristic is noted in the drug's pharmacokinetic profile.

Q: What is the difference between Reta and other medicines used for similar conditions?

A: Reta belongs to a class known as Angiotensin II Receptor Blockers (ARBs). Mechanistically, this class works by selectively blocking the AT1 receptor. This action distinguishes it from other blood pressure medicines, like ACE inhibitors, which block the formation of Angiotensin II.

Q: Is Reta considered a controlled substance or does it have a special safety classification?

A: Official regulatory sources classify Reta as an Angiotensin II Receptor Blocker (ARB) and a prescription-only medicine. The drug is not classified as a controlled substance by major government drug authorities.

Q: Can Reta still be effective if I miss a dose occasionally?

A: Official prescribing information addresses the circumstances surrounding missed doses. Patients are generally advised to follow specific instructions about whether to take a forgotten dose or wait for the next scheduled dose, as instructed by the prescriber.

Q: What are the most commonly reported side effects of Reta?

A: Clinical trials for the management of high blood pressure found that the most frequently reported adverse events at similar rates to placebo include headache, fatigue, and dizziness. Official product labels list these effects as common.

Q: Do the common side effects of Reta usually go away over time?

A: Official product information notes that, in general, adverse reactions reported during clinical development were mild and transient. Certain effects, such as dizziness, were documented to be generally transient, suggesting they may subside as a patient continues taking the medication.

Q: Is it safe to use Reta if I occasionally drink alcohol?

A: The consumption of alcohol (ethanol) and Reta can have an additive effect in lowering blood pressure. This combination may increase the risk of experiencing low blood pressure symptoms, such as lightheadedness or dizziness, which is most likely when initiating treatment.

Q: Is Reta an option for older adult patients?

A: Official regulatory documents state that no initial dose adjustment is typically required for older adult patients. However, pharmacokinetic studies show that the overall exposure to the drug may be higher in this population.

Q: Has Reta been studied in different patient populations or with other health conditions?

A: Yes, Reta has been investigated through clinical trials in several distinct patient groups. These trials include participants with high blood pressure, heart failure, and those receiving treatment following a myocardial infarction.

Q: Does Reta treat the main cause of the condition or just the symptoms?

A: Reta works by interfering with the Renin-Angiotensin System, which is a key mechanism that regulates blood pressure. By blocking the effects of a substance that tightens blood vessels, the drug directly addresses a primary underlying mechanism of the conditions it is indicated to treat.

Q: Can I stop taking Reta if I start feeling better?

A: Regulatory documents indicate that Reta is prescribed for chronic conditions that require consistent, continuous use. Stopping the medication abruptly is associated with the possibility of the underlying condition worsening or returning rapidly. For example, sudden cessation of medication intended to manage blood pressure may result in elevated blood pressure.

Q: Are there any known drug-disease interactions with Reta?

A: Official warnings and precautions detail certain drug-disease interactions. These include documented restrictions or requirements for cautious use in the presence of conditions such as severe congestive heart failure, bilateral renal artery stenosis, or volume depletion.

Q: Does Reta have any known interactions with herbal supplements or vitamins?

A: The official labeling warns specifically about supplements that contain potassium. Due to the mechanism of Reta, taking potassium supplements may lead to an elevated level of potassium in the blood.

Q: Can Reta cause changes in mood or sleep patterns?

A: Adverse event reports have included rare occurrences of changes in mood, such as anxiety, and disturbances in sleep patterns, such as insomnia. These are noted in the post-marketing surveillance data.

Q: Does Reta have a risk of dependence or withdrawal symptoms?

A: Regulatory sources do not classify Reta as having a potential for dependence or formal addiction. However, abrupt discontinuation of medication intended for chronic conditions is associated with the possibility of the underlying condition worsening, such as an increase in blood pressure.

Q: Is there a possibility of an allergic reaction to Reta, and what are the signs?

A: A serious, but rare, allergic reaction known as Angioedema is a documented safety concern. Signs include swelling of the face, tongue, throat, or lips, or difficulty breathing or swallowing. These signs indicate a severe reaction that is documented to require prompt medical evaluation.

Q: Why do some people experience fatigue while taking Reta?

A: Fatigue is officially listed as a common adverse event experienced by participants in clinical trials. While product labeling does not detail the specific physiological reason for this effect, it is a known occurrence reported with the medication.

Q: Is the onset of action of Reta immediate or gradual?

A: The onset of Reta's blood pressure-lowering effect is gradual. Although the initial activity begins within approximately two hours, the full, maximal effect is realized only after several weeks of consistent use.

Q: Does Reta have a common effect on blood pressure or heart rate?

A: Reta is intended to lower blood pressure, and low blood pressure (hypotension) is a common side effect, especially in patients with heart failure. Effects on heart rate are not frequently reported, although palpitations are noted as an infrequent adverse event.

How should Reta be stored and disposed of?

Reta (Valsartan oral tablet) must be stored and handled according to specific conditions defined in official regulatory labeling to maintain stability.

Storage Requirements

Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature (CRT), 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and away from excessive heat and moisture.
Container Store in the original container and protect it from light.
Child Safety Must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired Reta should be discarded using a drug take-back program. If a take-back option is unavailable, the tablets should be removed from their original container, mixed with an undesirable substance (e.g., used coffee grounds or dirt), sealed in a bag or container, and placed in the household trash. Do not flush the medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reta found in:

A-Z Index: